Fundraising Fox

Takeda Ventures

Corporate VC

Pre-Seed–Late Stage · 17 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

Takeda Ventures partners with academic innovators and entrepreneurs to build and manage a portfolio of companies focused on therapeutic innovation in oncology, rare genetics and hematology, neuroscience, and gastrointestinal and inflammation areas. As a strategic investor, the firm aims to generate disruptive technologies and therapeutic solutions while providing portfolio companies access to resources and expertise from a multinational pharmaceutical organization.

Source: firm website, verified Jul 21, 2026.

Stage
Pre-Seed–Late Stage
Instruments
Equity
Founded
2001

Team · 17 people

from the firm's website
Julie Kim· Representative Director – President and CEO
Akiko Amakawa· CEO Chief of Staff
Andrew S. Plump· Director - President, Research & Development
Asuka Miyabashira· President, Japan Pharma Business Unit
Awny Farajallah· Chief Medical Officer
Elaine Shannon· President, Global Supply & Quality
Gabriele Ricci· Chief Data & Technology Officer
Giles Platford· President, International Business Unit
Jennifer Smoter· Chief Communications & Governance Officer
Lauren Duprey· Chief Transformation Officer
Marcello Agosti· Interim Head, Strategy & Portfolio Development
Milano Furuta· Director – Chief Financial Officer
Natalie Furney· Global General Counsel
Nicola Greenway· Chief Human Resources Officer
Ramy Riad· President, Plasma-Derived Therapies Business Unit
Rhonda Pacheco· President, U.S. Business Unit and U.S. Country Head
Teresa Bitetti· President, Global Oncology Business Unit

Frequently asked questions

What stage does Takeda Ventures invest at?
Takeda Ventures invests at the Pre-Seed, Seed, Late Stage stages.
What sectors does Takeda Ventures focus on?
Takeda Ventures focuses on Biotech, Medical Devices.

Similar investors

B Capital Group

B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.

DCVC (Data Collective)

DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.

Medicxi

A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.

Osage University Partners

Osage University Partners is a venture capital firm founded in 2009 that invests in breakthrough startups emerging from leading research labs and university innovation ecosystems. The firm focuses on technology (software, hardware, climate tech) and life science (therapeutics, medtech, diagnostics, research tools) companies across all stages from pre-seed through crossover, leveraging partnerships with over 150 universities and research institutions globally.

$1M – $20M
F-Prime Capital Partners

F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.

Featured in lists